Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT03947385 |
TitleStudy of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | Phase
Phase 1, Phase 2
|
Date Added 2019-05-13 |
Location
California, United States
New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Australia Canada |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Binimetinib, Crizotinib, IDE196 |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04014530 |
TitlePembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study | Phase
Phase 1
|
Date Added 2019-07-10 |
Location
Netherlands
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Ataluren + Pembrolizumab, Keytruda |
Tags
MSS/ MMRp
|
| NCT ID NCT04874259 |
TitleLT for Unresectable Colorectal Liver Metastasis | Phase
Not Applicable
|
Date Added 2021-05-05 |
Location
Korea, Republic of
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT01697371 |
TitleProton Therapy in the Treatment of Liver Metastases | Phase
Not Applicable
|
Date Added 2012-10-02 |
Location
California, United States
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06322693 |
TitleA Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) | Phase
Phase 1
|
Date Added 2024-03-21 |
Location
Arizona, United States
California, United States Colorado, United States Connecticut, United States District of Columbia, United States Florida, United States Georgia, United States Illinois, United States Iowa, United States Kansas, United States Kentucky, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States Korea, Republic of Spain |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Carboplatin, cisplatin, Docetaxel, Nivolumab, Pemetrexed, TSR-022, TSR-033, TSR-042 |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03412877 |
TitleAdministration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer | Phase
Phase 2
|
Date Added 2018-01-29 |
Location
Maryland, United States
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs
Aldesleukin, Cyclophosphamide, Fludarabine, Individual Patient TCR-Transduced PBL, Pembrolizumab (Keytruda) |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03985891 |
TitleThe Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer | Phase
Phase 1/Phase 2
|
Date Added 2019-06-14 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Anti-PD-1 Monoclonal Antibody JS001, Chemotherapy |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04104776 |
TitleA Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas | Phase
Phase 1
|
Date Added 2019-09-26 |
Location
Georgia, United States
Illinois, United States Maryland, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Pennsylvania, United States Texas, United States Virginia, United States Washington, United States France Italy Korea, Republic of Poland Spain United Kingdom |
Prior IO Allowed No |
CRC-directed No |
Status
Recruiting
|
Drugs
CPI-0209, CPI-0209 |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05019534 |
TitleTolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer | Phase
Phase 1
|
Date Added 2021-08-25 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Camrelizumab, Cetuximab Injection [Erbitux], Vemurafenib Oral Tablet [Zelboraf] |
Tags
MSS/ MMRp
|
| NCT ID NCT03868228 |
TitlePIPAC for the Treatment of Colorectal Peritoneal Metastases | Phase
Phase 1
|
Date Added 2019-03-11 |
Location
United Kingdom
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
